Egenesis was last valued at $350M (post-money). It comes from the $125M Series C of Feb 2021. The company is private, so there is no listed share price.
1 valuation. The latest, $350M post-money, was set by the Series C in Feb 2021.
A private valuation is the price agreed in one transaction. The Egenesis valuation of $350M is a post-money figure from the Series C dated 1 Feb 2021 — the whole company measured after the $125M raised in that round was already inside it. Subtract the round and the pre-money view of the same deal is $225M .
The valuation holds until the next priced round or secondary sale. A private company founded in 2015 with roughly 200 people has no daily price and no order book between rounds.
The closest biotechnology / healthcare peers are on the competitors page.
The routes section explains what is realistically available for a company at this stage.
No. Egenesis is a private company; its shares do not trade on a public exchange.
The last valuation is $350M.
Lead investors for each round are in the funding timeline.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
